Entering text into the input field will update the search result below
Create free account
Search for Symbols, analysts, keywords
Log in
Analysis
All Analysis
Basic Materials
Biotech
Bonds
Closed End Funds
Commodities
Communication Services
Consumer
Consumer Staples
Cryptocurrency
Dividend Ideas
Dividend Quick Picks
Dividend Strategy
Dividends
Economy
Editors' Picks
Energy
ETF Analysis
ETFs and Funds
Financial Advisor
Financials
Fixed Income
Forex
Gold & Precious Metals
Growth
Healthcare
Industrial
Investing Strategy
IPOs
Long Ideas
Market Outlook
Micro-Caps
Mutual Funds
Portfolio Strategy
Quick Picks & Lists
Real Estate
REITs
Retirement
Small-Caps
Stock Ideas
Tech
Utilities
Value
Latest Healthcare & Biotech Stock Analyses
Immatics N.V.: An Intriguing Developmental Concern
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade)
Doximity: Significant Upside Remains, But Not Until The Growth Story Returns
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
Alignment Healthcare: A First Assessment
Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
FOMC Meeting, Jobs Report, And Apple Earnings Headline Big Week
AstraZeneca: A Triple Shot Of Income, Growth, And Value
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform
Diving Into Deciphera Pharmaceuticals
Canopy Growth Set For U.S. Cannabis Markets
Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
MindMed: Breakthrough Status From The FDA For LSD Therapy
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off
SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
ClearPoint Neuro: Macro-Induced Multiple Compression
Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.
Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
WuXi Biologics: Staying On The Sidelines
Roivant Sciences: Cashing In On Vants And Ventures
Bruker Corporation: An Aggressive Acquisition Strategy
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Crispr Therapeutics: Now Is The Time To Buy
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression
Evotec: Still A Speculative Buy After A Significant Decline
Aurora Cannabis: Improved Financials, Limited Opportunity
1
2
3
4
5
Next